Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
about
Allogeneic stem cell transplantation in first complete remissionComprehensive mutational profiling of core binding factor acute myeloid leukemia.Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemiasPrognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.Molecular signatures in acute myeloid leukemia.Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysisAcute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaCore-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations.Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia.Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia.Treatment of AML in biological subgroups.Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype.Prognostic markers in AML: focus on CBFLHLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia.Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group.Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.Prognosis of patients with core binding factor acute myeloid leukemia after first relapseTherapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.Interactive diagnostics in the indication to allogeneic SCT in AML.The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects.High-dose cytarabine (HD araC) in the treatment of leukemias: a review.Should persons with acute myeloid leukemia have a transplant in first remission?Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.Single-nucleotide polymorphism-array improves detection rate of genomic alterations in core-binding factor leukemia.Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups.Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia.KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.Minimal residual disease in acute myeloid leukemia--current status and future perspectives.
P2860
Q26996818-B9466984-B7E3-4999-A250-A86DCC31C035Q33758306-F63C7AA7-8844-4133-9E6A-F637FDBF2EECQ34018590-19A1BC4F-0992-4C9C-A2BE-090CB4B99B7AQ34106837-E3EAFD1A-7831-4865-A3B4-5705FB7C554DQ34169601-29DA129E-ED25-4BAB-99E3-EAB4ADB74A05Q34255090-25124D97-A1EC-4FED-9724-F539EEA6534AQ34285901-A5C80927-85A0-457E-8D3A-1B0364334AC1Q34403639-FC88CBAC-D50B-483F-B08A-02DB58781A41Q34428556-F2B17744-2611-4877-96A4-EB27AF539B1DQ34578418-75AD4726-7E10-4F6D-AE0B-6CE8C97D8BD8Q34598109-F4382D83-EF65-46C0-B4B7-C4B46CCC8AD9Q34663691-6DFD57AE-B8DE-4A9D-9161-2FF5A690669BQ35361598-6B2767BD-E110-4721-A823-51F4B70E5D88Q35849281-1A975F70-0B9A-43F1-810E-1591F1D01115Q35877004-AAEA94F8-B124-4CC4-BEDB-7F2AA1C7380EQ36255287-E0855B0A-9C28-4F51-AA43-1CE03AAEA00FQ36308975-E5DF9B7E-4251-49E5-A942-A3178FB7D71AQ36457184-D5BFD519-4024-4085-A837-BBE7058BA9E7Q36529502-9C54A94B-E11D-484B-95CA-4542860D46B6Q36808186-31866629-4757-4323-A32B-E8B349CB09F7Q36852251-DEC959AE-C7FA-4646-91F7-33094640EE56Q36865630-FD5B305D-3E38-4011-AC51-BF473514F69CQ36919799-254D9603-B230-4CE1-9BB4-2CE76C4CBFD3Q37002149-55FC6020-836E-4743-835A-055677C1A49FQ37149438-FD7B71B7-355A-4D85-8DD8-5DBA642EC556Q37159533-3474824B-9B90-46C8-9299-2491043AF7C1Q37212688-2D989F60-C28B-46CB-9505-D55D631D7A79Q37372832-FDEDB07F-4CDE-4462-8FF0-08C6A9FC9CA2Q37442649-B11578C7-4558-4576-858B-0B4CFE2F3CE6Q37628021-8299B4F2-1850-4F6B-BB08-7E3A0E3EE4D0Q37871413-8E45D129-02B3-4399-972F-910F3055BF55Q38105942-13117D94-F833-41FA-B903-76B5999B50ADQ38204207-C7D9AC78-3A71-4F7F-9BC5-3B1C116EEF1BQ38263126-4992E994-2AFC-4D1D-B252-C756472BDA41Q38315894-F95F545E-88F8-466D-B1E1-044B05A3FF1CQ38333998-FEEEFD68-2C9A-4382-88D9-F62D3DEC9974Q38352241-CD7B43E8-92D5-4001-BD9E-30006EA18B96Q38457561-D0ACB858-7463-496A-8504-EFACF845050EQ38459577-4ADAA307-AC68-4C32-92EA-06E51845CCA7Q38494659-68D41FDE-A47F-4751-8F36-8170F17ED7F5
P2860
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Individual patient data-based ...... e Myeloid Leukemia Intergroup.
@ast
Individual patient data-based ...... e Myeloid Leukemia Intergroup.
@en
type
label
Individual patient data-based ...... e Myeloid Leukemia Intergroup.
@ast
Individual patient data-based ...... e Myeloid Leukemia Intergroup.
@en
prefLabel
Individual patient data-based ...... e Myeloid Leukemia Intergroup.
@ast
Individual patient data-based ...... e Myeloid Leukemia Intergroup.
@en
P2093
P356
P1476
Individual patient data-based ...... e Myeloid Leukemia Intergroup.
@en
P2093
Ehninger G
P304
P356
10.1200/JCO.2004.03.012
P407
P577
2004-08-02T00:00:00Z